Kerr, J R, Cunniffe, V S, Kelleher, P et al. · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2003 · DOI
This study looked at three patients whose chronic fatigue syndrome (ME/CFS) appeared to start after they were infected with parvovirus B19, a common virus. These patients were treated with intravenous immunoglobulin (IVIG), a therapy that contains antibodies from donated blood. All three patients improved significantly, with their symptoms resolving and their ability to function returning to normal.
This study is significant because it suggests that some cases of ME/CFS may be triggered by persistent parvovirus B19 infection and that a specific, directed treatment might be effective in these cases. The improvement in both symptoms and immune markers raises important questions about whether viral persistence and immune dysregulation are mechanistic factors in at least a subgroup of ME/CFS patients.
This study does not prove that parvovirus B19 causes ME/CFS in the general patient population, as it only describes three cases. It does not establish that IVIG would be effective for ME/CFS patients without documented parvovirus B19 infection, nor does it determine whether the improvement was due to IVIG's antiviral properties, its immune-modulating effects, or another mechanism. The lack of a control group means we cannot definitively attribute outcomes to the treatment rather than natural recovery.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.